Remix Therapeutics | ApexOnco - Clinical Trials news and analysis

x

“Top quality, fast and so easy to use”

Director New Product Planning

Morphosys

Click here for more information

Trial results

13 November 2023

Phase 1 entrants seek improved safety

First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.

Subscribe to Remix Therapeutics